lapatinib monomesylate | 1092928-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: lapatinib monomesylate
• 英文别名: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;methanesulfonic acid
• CAS: 1092928-98-7
• 化学式: CH₄O₃S*C₂₉H₂₆ClFN₄O₄S
• 分子量: 677.174
• InChiKey: QCRBRCCJLFHRRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.64
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  178
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  拉帕替尼 、 甲烷磺酸 以 丙醇 为溶剂， 以93.2%的产率得到lapatinib monomesylate
  参考文献：
  名称：

  WO2008/154469

  摘要：

  公开号：

文献信息

• METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINE BOX KIT
  申请人：Chia Tai Tianqing Pharmaceutical Group Co.,Ltd

  公开号：EP3153169A1

  公开（公告）日：2017-04-12

  The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.

  本发明提供了用于防治肿瘤的 1-[[[4-(4-氟-2-甲基-1H-吲哚-5-基)氧基-6-甲氧基喹啉-7-基]氧基]甲基]环丙基胺。具体而言，本发明是指与所述化合物相关的治疗肿瘤的方法、药物组合物和药包。以合适的剂量方案服用该化合物，不仅能使患者血浆浓度维持在 100 ng/ml 或更低水平，还能达到治疗效果，对各种肿瘤均有益处。
• Method for treating tumour, pharmaceutical composition and medicinal kit
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US10251876B2

  公开（公告）日：2019-04-09

  The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.

  本发明提供了用于防治肿瘤的 1-[[[4-(4-氟-2-甲基-1H-吲哚-5-基)氧基-6-甲氧基喹啉-7-基]氧基]甲基]环丙基胺。 具体而言，本发明是指与所述化合物相关的治疗肿瘤的方法、药物组合物和药包。 以合适的剂量方案服用该化合物，不仅能使患者血浆浓度维持在 100 ng/ml 或更低水平，还能达到治疗效果，对各种肿瘤均有益处。
• USING CATEQUENTINIB (ANLOTINIB) COMBINING WITH STANDARD CHEMOTHERAPY OR IMMUNOTHERAPY IN SEQUENTIAL ORDER FOR THE CANCER TREATMENT
  申请人：Advenchen Pharmaceuticals LLC

  公开号：EP3934645A1

  公开（公告）日：2022-01-12
• METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINAL KIT
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

  公开号：US20170182027A1

  公开（公告）日：2017-06-29

  The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.
• USES OF EGFR/HER2 INHIBITOR COMBINED WITH PYRIMIDINE-TYPE ANTI-METABOLIC DRUG
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US20190358212A1

  公开（公告）日：2019-11-28

  Uses of an EGFR/HER2 inhibitor combined with a pyrimidine-type anti-metabolic drug are provided. Specifically, uses of an EGFR/HER2 receptor tyrosine kinase inhibitor combined with pyrimidine-type anti-metabolic drug in the preparation of drugs for treating cancers are provided.